Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 3/20 | 0.45 |
| ▸ | TTR | P02766 | 2/20 | 0.42 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | CA3 | P07451 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 2/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL850504 | 0.85 | TPMT (0.54) | TPMTTTRHCAR1CA12CA1 | |
| SCHEMBL2011335 | 0.79 | NOTUM (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23699536 | 0.79 | TPMT (0.48) | TPMTTTRHCAR1CA12CA1 | |
| SCHEMBL25981011 | 0.78 | CA12 (0.52) | TPMTTTRHCAR1CA12CA1 | |
| SCHEMBL27300557 | 0.78 | TPMT (0.46) | TPMTTTRHCAR1CA12CA1 | |
| SCHEMBL15197099 | 0.77 | CA12 (0.58) | TPMTTTRCA12CA1CA2 | |
| SCHEMBL31395250 | 0.76 | TPMT (0.54) | TPMTTTRHCAR1CA12CA1 | |
| SCHEMBL31700656 | 0.76 | TPMT (0.45) | TPMTTTRHCAR1CA12CA1 | |
| SCHEMBL23699555 | 0.76 | TTR (0.52) | TPMTTTRHCAR1CA12CA1 | |
| SCHEMBL31701026 | 0.76 | TTR (0.52) | TPMTTTRHCAR1HSD17B10MYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163730-B2 | Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-04-24 | — | — | US | disclosed |
| US-7964631-B2 | Fused tricyclic compounds as inhibitors of tumor necrosis factor-α | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100324026-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-12-23 | — | — | US | disclosed |
| US-20100305094-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-12-02 | — | — | US | disclosed |
| US-7834052-B2 | Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-11-16 | — | — | US | disclosed |
| US-20070299050-A1 | Fused Tricyclic Compounds as Inhibitors of Tumor Necrosis Factor-Alpha | NICHOLAS PIRAMAL INDIA LIMITED. (IN) | 2007-12-27 | — | — | US | disclosed |
| EP-1812419-A2 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | Nicholas Piramal India Limited (IN) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006051477-A2 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324026-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | CD40, TNFRSF1A, OXER1 | TPMT 1222/4885TTR 2513/4885HCAR1 94/4885 |
| US-20070299050-A1 | Fused Tricyclic Compounds as Inhibitors of Tumor Necrosis Factor-Alpha | CD40, TNFRSF1A, OXER1 | TPMT 1241/4885TTR 2928/4885HCAR1 97/4885 |
| US-20100305094-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | CD40, TNFRSF1A, OXER1 | TPMT 1241/4885TTR 2928/4885HCAR1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.